Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: J Immunol. 2017 Oct 30;199(11):3828–3839. doi: 10.4049/jimmunol.1700426

Figure 6. FH6-7/hFc increases survival in experimental S. pyogenes sepsis.

Figure 6

FH6-7/hFc treated human FH transgenic mice show reduced mortality in an experimental i.v. S. pyogenes sepsis model. Human FH transgenic mice (n=10/group) were treated with either FH6-7/hFc or goat IgG (control that does not bind S. pyogenes) i.p. with the dosing schedule shown on the X-axis. Statistical significance of differences was calculated using a Mantel-Cox analysis.